Get informed when a big investor buys or sells
+ FollowUndervalued by 88191% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $1.40 Million |
|---|---|
| Enterprise Value | $1.10 Billion |
| Earnings per Share | $6.44 |
| Beta | 0.98 |
| Outstanding Shares | 19,962,000 |
| P/E Ratio | 119.22 |
|---|---|
| PEG | -75.88 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | 4.33 |
| Enterprise Value to EBIT | 8.96 |
| Enterprise Value to Net Income | 54 |
| Total Debt to Enterprise | 1.05 |
| Debt to Equity | 1.2 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Ligand Pharmaceuticals, Inc. functions as a biopharmaceutical firm, primarily focusing on developing and acquiring innovative technologies that empower other pharmaceutical companies in their drug discovery and development processes. Its...
Stockcircle shows 20 open-market insider sales for Ligand Pharmaceuticals in the last six months from SEC Form 4 reports by executives, directors, and other insiders.
Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.